Literature DB >> 18413612

Alteration of cyclin D1 transcript elongation by a mutated transcription factor up-regulates the oncogenic D1b splice isoform in cancer.

Gabriel Sanchez1, Danielle Bittencourt, Karine Laud, Jérôme Barbier, Olivier Delattre, Didier Auboeuf, Martin Dutertre.   

Abstract

Pre-mRNA splicing and polyadenylation are tightly connected to transcription, and transcriptional stimuli and elongation dynamics can affect mRNA maturation. However, whether this regulatory mechanism has a physio/pathological impact is not known. In cancer, where splice variant expression is often deregulated, many mutated oncogenes are transcriptional regulators. In particular, the Ewing sarcoma (EwSa) oncogene, resulting from a fusion of the EWS and FLI1 genes, encodes a well characterized transcription factor. EWS-FLI1 directly stimulates transcription of the CCND1 protooncogene encoding cyclin D1a and a less abundant but more oncogenic splice isoform, D1b. We show that, although both EWS and EWS-FLI1 enhance cyclin D1 gene expression, they regulate the D1b/D1a transcript ratio in an opposite manner. Detailed analyses of RNA polymerase dynamics along the gene and of the effects of an inhibitor of elongation show that EWS-FLI1 favors D1b isoform expression by decreasing the elongation rate, whereas EWS has opposite effects. As a result, the D1b/D1a ratio is elevated in EwSa cell lines and tumors. The endogenous D1b protein is enriched in nuclei, where the oncogenic activity of cyclin D1 is known to occur, and depleting D1b in addition to D1a results in a stronger reduction of EwSa cell growth than depleting D1a only. These data show that elevated expression of a splice isoform in cancer can be due to an alteration of the transcription process by a mutated transcriptional regulator and provide evidence for a physio/pathological impact of the coupling between transcription and mRNA maturation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18413612      PMCID: PMC2329709          DOI: 10.1073/pnas.0710748105

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  39 in total

Review 1.  Function of alternative splicing.

Authors:  Stefan Stamm; Shani Ben-Ari; Ilona Rafalska; Yesheng Tang; Zhaiyi Zhang; Debra Toiber; T A Thanaraj; Hermona Soreq
Journal:  Gene       Date:  2004-12-10       Impact factor: 3.688

Review 2.  EWS-ETS oncoproteins: the linchpins of Ewing tumors.

Authors:  Ralf Janknecht
Journal:  Gene       Date:  2005-10-03       Impact factor: 3.688

Review 3.  Rules of engagement: co-transcriptional recruitment of pre-mRNA processing factors.

Authors:  David L Bentley
Journal:  Curr Opin Cell Biol       Date:  2005-06       Impact factor: 8.382

4.  The human SWI/SNF subunit Brm is a regulator of alternative splicing.

Authors:  Eric Batsché; Moshe Yaniv; Christian Muchardt
Journal:  Nat Struct Mol Biol       Date:  2005-12-11       Impact factor: 15.369

Review 5.  Controlling the elongation phase of transcription with P-TEFb.

Authors:  B Matija Peterlin; David H Price
Journal:  Mol Cell       Date:  2006-08-04       Impact factor: 17.970

Review 6.  The connection between splicing and cancer.

Authors:  Anabella Srebrow; Alberto R Kornblihtt
Journal:  J Cell Sci       Date:  2006-07-01       Impact factor: 5.285

Review 7.  Location, location, location: the role of cyclin D1 nuclear localization in cancer.

Authors:  Andrew B Gladden; J Alan Diehl
Journal:  J Cell Biochem       Date:  2005-12-01       Impact factor: 4.429

8.  Transcriptional activators differ in their abilities to control alternative splicing.

Authors:  Guadalupe Nogues; Sebastian Kadener; Paula Cramer; David Bentley; Alberto R Kornblihtt
Journal:  J Biol Chem       Date:  2002-09-06       Impact factor: 5.157

Review 9.  Unbalanced alternative splicing and its significance in cancer.

Authors:  Julian P Venables
Journal:  Bioessays       Date:  2006-04       Impact factor: 4.345

10.  Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation.

Authors:  Craig J Burd; Christin E Petre; Lisa M Morey; Ying Wang; Monica P Revelo; Christopher A Haiman; Shan Lu; Cecilia M Fenoglio-Preiser; Jiwen Li; Erik S Knudsen; Jiemin Wong; Karen E Knudsen
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-06       Impact factor: 11.205

View more
  53 in total

1.  Cotranscriptional exon skipping in the genotoxic stress response.

Authors:  Martin Dutertre; Gabriel Sanchez; Marie-Cécile De Cian; Jérôme Barbier; Etienne Dardenne; Lise Gratadou; Gwendal Dujardin; Catherine Le Jossic-Corcos; Laurent Corcos; Didier Auboeuf
Journal:  Nat Struct Mol Biol       Date:  2010-10-24       Impact factor: 15.369

Review 2.  Oncogenic partnerships: EWS-FLI1 protein interactions initiate key pathways of Ewing's sarcoma.

Authors:  Hayriye V Erkizan; Vladimir N Uversky; Jeffrey A Toretsky
Journal:  Clin Cancer Res       Date:  2010-06-14       Impact factor: 12.531

3.  Global impact of RNA polymerase II elongation inhibition on alternative splicing regulation.

Authors:  Joanna Y Ip; Dominic Schmidt; Qun Pan; Arun K Ramani; Andrew G Fraser; Duncan T Odom; Benjamin J Blencowe
Journal:  Genome Res       Date:  2010-12-16       Impact factor: 9.043

Review 4.  New tricks from an old oncogene: gene fusion and copy number alterations of MYB in human cancer.

Authors:  Göran Stenman; Mattias K Andersson; Ywonne Andrén
Journal:  Cell Cycle       Date:  2010-08-28       Impact factor: 4.534

Review 5.  Chromatin's thread to alternative splicing regulation.

Authors:  Camilla Iannone; Juan Valcárcel
Journal:  Chromosoma       Date:  2013-08-03       Impact factor: 4.316

Review 6.  Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged.

Authors:  Charles J David; James L Manley
Journal:  Genes Dev       Date:  2010-11-01       Impact factor: 11.361

7.  Alternative splicing of the cyclin D1 proto-oncogene is regulated by the RNA-binding protein Sam68.

Authors:  Maria Paola Paronetto; Manuela Cappellari; Roberta Busà; Simona Pedrotti; Roberta Vitali; Clay Comstock; Terry Hyslop; Karen E Knudsen; Claudio Sette
Journal:  Cancer Res       Date:  2009-12-22       Impact factor: 12.701

8.  Cyclin K and cyclin D1b are oncogenic in myeloma cells.

Authors:  Véronique Marsaud; Guergana Tchakarska; Geoffroy Andrieux; Jian-Miao Liu; Doulaye Dembele; Bernard Jost; Joanna Wdzieczak-Bakala; Jack-Michel Renoir; Brigitte Sola
Journal:  Mol Cancer       Date:  2010-05-10       Impact factor: 27.401

9.  Downstream EWS/FLI1 - upstream Ewing's sarcoma.

Authors:  Heinrich Kovar
Journal:  Genome Med       Date:  2010-01-28       Impact factor: 11.117

10.  Cell Cycle Deregulation in Ewing's Sarcoma Pathogenesis.

Authors:  Ashley A Kowalewski; R Lor Randall; Stephen L Lessnick
Journal:  Sarcoma       Date:  2010-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.